Gofen & Glossberg LLC IL increased its position in Amgen Inc. (NASDAQ:AMGN) by 1.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,494 shares of the medical research company’s stock after buying an additional 377 shares during the period. Gofen & Glossberg LLC IL’s holdings in Amgen were worth $3,585,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in AMGN. Valley National Advisers Inc. raised its position in Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock worth $109,000 after buying an additional 33 shares in the last quarter. Glassman Wealth Services raised its stake in shares of Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock worth $110,000 after buying an additional 600 shares in the last quarter. Oakworth Capital Inc. raised its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Integrated Wealth Management raised its stake in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares in the last quarter. Finally, Delta Asset Management LLC TN raised its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded up 0.64% during trading on Tuesday, reaching $146.00. 2,938,912 shares of the company’s stock were exchanged. The company has a market capitalization of $108.61 billion, a PE ratio of 14.61 and a beta of 1.15. The company’s 50-day moving average is $151.01 and its 200-day moving average is $160.49. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $176.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.23. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the business posted $2.72 EPS. Equities research analysts expect that Amgen Inc. will post $11.56 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be given a dividend of $1.00 per share. The ex-dividend date of this dividend is Monday, November 14th. This represents a $4.00 annualized dividend and a dividend yield of 2.74%. Amgen’s dividend payout ratio (DPR) is currently 39.92%.

COPYRIGHT VIOLATION NOTICE: “Gofen & Glossberg LLC IL Raises Stake in Amgen Inc. (AMGN)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and reposted in violation of U.S. & international copyright law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2016/11/29/gofen-glossberg-llc-il-raises-stake-in-amgen-inc-amgn.html.

AMGN has been the topic of a number of analyst reports. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $166.35 price objective on the stock. in a report on Monday, August 1st. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $204.00 price objective on shares of Amgen in a report on Thursday, September 8th. Cowen and Company reaffirmed a “buy” rating on shares of Amgen in a report on Monday, September 19th. Leerink Swann reaffirmed a “market perform” rating and issued a $163.00 price objective (down previously from $193.00) on shares of Amgen in a report on Friday, October 28th. Finally, Piper Jaffray Cos. set a $193.00 price target on Amgen and gave the stock a “buy” rating in a research note on Thursday, September 15th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $182.04.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.